News >

Alpelisib Improves PFS in PIK3CA+ Advanced Breast Cancer

Published: Thursday, Aug 23, 2018

Samit Hirawat, executive vice president and head, Global Drug Development at Novartis Oncology

Samit Hirawat
Combining Alpelisib (BYL719) with fulvestrant (Faslodex) improved progression-free survival versus fulvestrant alone in postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutant advanced or metastatic breast cancer that progressed after aromatase inhibitor treatment with or without a CDK4/6 inhibitor, meeting the primary endpoint of the phase III SOLAR-1 trial.

–wild-type tumors including 5 with ER-positive/HER2-negative breast cancer, 1 in the dose-escalation phase and 4 in the dose-expansion phase. The most common primary cancer sites were breast (n = 36; 26.9%), colorectal (n = 35; 26.1%), and head and neck (n = 19; 14.2%).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication